Bulevirtide: First Approval.

Article Details

Citation

Copy to clipboard

Kang C, Syed YY

Bulevirtide: First Approval.

Drugs. 2020 Oct;80(15):1601-1605. doi: 10.1007/s40265-020-01400-1.

PubMed ID

32926353 [ View in PubMed

]

Abstract

Bulevirtide (Hepcludex((R))), a first-in-class entry inhibitor, is being developed by MYR GmbH for the treatment of chronic hepatitis delta virus (HDV) and chronic hepatitis B virus (HBV) infections. Bulevirtide was recently approved in the European Union (EU) for the treatment of chronic HDV infection in HDV RNA positive adult patients with compensated liver disease. This article summarizes the milestones in the development of bulevirtide leading to this first approval for chronic HDV.

DrugBank Data that Cites this Article

Drugs

Bulevirtide

Drug Targets

Drug	Target	Kind	Organism	Pharmacological Action	Actions
Bulevirtide	Sodium/bile acid cotransporter	Protein	Humans	Yes	Inhibitor	Details